European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.
(Bloomberg) -- Pharmaceutical giant AbbVie Inc. sold $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings. Most Read from BloombergNvidia Rises Most in About Nine Months as AI Drives SalesT-Bills Without Tax Bills? This Fund Says It Cracked the CodeStocks Rally as AI Craze Sweeps Across the World: Markets WrapAT&T Outage Triggered by Company Work on N
AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie's expertise in oncology and immunology with Tentarix's proprietary Tentacles™ platform.